In 2022, Strateos revenue run rate hit $6.6M in revenue.
Strateos hit $6.6M in revenue in 2021
Strateos launched in 2012 with $0 revenue
Strateos Funding History
Why are so many SaaS founders taking money from Founderpath.com instead of VC`s?
Strateos raised a of $16.5M
Strateos raised a of $13.4M
Strateos raised a of $8.5M
Strateos raised a of $120K
Strateos raised a of $1.8M
Strateos raised a of $2.8M
Strateos raised a of $1.2M
Strateos has 85 total employees
Total team size
Mark Fischer-Colbrie became CEO of Strateos in May 2019 following the successful sale of Labcyte Inc., a global laboratory tools company, to Danaher. He has more than 30 years of experience in building and growing laboratory tools, diagnostic, medical device and therapeutic companies, including 3 Initial Public Offerings. In 2013, Mark was named National Finalist, Life Sciences for the Ernst & Young National Entrepreneur of the Year and Entrepreneur of the Year, Life Sciences for Northern California. Prior to Strateos, Mark was CEO for over ten years at Labcyte Inc. which invented novel lab tools and automation based on acoustic dispensing. Before Labcyte, Mark ran business development and was CFO at Adeza Biomedical Corporation, a women’s healthcare company, where he filed 9 patent applications and set up and ran clinical trials for diagnostics. Prior to Adeza, Mark was the CFO for 9 years for a vision correction company that went public and launched a Class III medical device. Mark holds a BA from Stanford and an MBA in marketing / finance from UC Berkeley. Mark has served as Chairman of JDRF’s International Board of Directors, the largest global funder of type one diabetes research, and served on the JDRF IBOD for seven years. Mark has also served on the industry board of the Analytical, Life Sciences Diagnostics Association (ALDA) since 2011. Mark enjoys participating in long distance triathlon and running events.